Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral
tablets, patients experience withdrawal and cravings when the variable BPN levels in the
blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin
that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study
will test the safety and efficacy of Probuphine in the treatment of patient with opioid
dependence. Patients who have completed 24 weeks of treatment in the Randomized,
Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid
Dependence, will be re-treated with Probuphine over an additional 24 weeks.